Generic Name and Formulations:
Dichlorphenamide 50mg; scored tabs.
Indications for KEVEYIS:
Primary hyperkalemic or hypokalemic periodic paralysis and related variants.
Initially 50mg twice daily. Adjust dose based on response, at weekly intervals (or sooner if adverse reactions occur); max 200mg daily. Evaluate after 2 months.
Concomitant high-dose aspirin. Severe pulmonary disease. Hepatic insufficiency. Sulfonamides.
Discontinue at first sign of skin rash or immune-mediated or idiosyncratic adverse reaction. Adrenocortical insufficiency, hyperchloremic metabolic acidosis, respiratory acidosis: increased risk of hypokalemia. Metabolic acidosis. Monitor serum potassium and bicarbonate at baseline and periodically during treatment; reduce dose or discontinue if hypokalemia or metabolic acidosis develops. Increased risk of falls (esp. elderly, higher doses); consider dose reduction or discontinuation if occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.
Caution with concomitant low-dose aspirin. Increased risk of hypokalemia with loop or thiazide diuretics, laxatives, antifungals, penicillin, and theophylline.
Carbonic anhydrase inhibitor.
Paresthesia, cognitive disorder, dysgeusia, confusion, hypoesthesia, lethargy, dizziness, nausea, fatigue, muscle spasms, rash; hypersensitivity reactions.